-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Peripheral T-cell lymphoma (PTCL) is a relatively rare heterogeneous malignant tumor, accounting for approximately 10% of all non-Hodgkin’s lymphomas (NHLs) in the Western population
Peripheral T-cell lymphoma (PTCL) is a relatively rare heterogeneous malignant tumor, accounting for approximately 10% of all non-Hodgkin’s lymphomas (NHLs) in the Western population
CD30 is highly expressed in sALCL, but its expression in patients with other PTCL subtypes varies greatly
From January 24, 2013 to November 07, 2016, a total of 452 patients from 17 countries were randomly assigned to receive A+CHP treatment (N=226) or CHOP treatment (N=226), with a median follow-up time 66.
From January 24, 2013 to November 07, 2016, a total of 452 patients from 17 countries were randomly assigned to receive A+CHP treatment (N=226) or CHOP treatment (N=226), with a median follow-up time 66.
The median progression-free survival (PFS) of patients in the A+CHP group was 62.
Differences in the treatment of PFS between the general population and the two groups of sALCL patients
Among AITL patients, the 5-year PFS rate of the A+CHP group was 26.
The median OS of the two groups did not reach 0.
Differences in the treatment of OS between the general population and sALCL patients
Among AITL patients, the 5-year OS rates of the two groups were 67.
Of the 226 patients in the A+CHP group, 29 (13%) were treated with brentuximab vedotin (bentuximab) after progression or recurrence, and 54 of the 226 patients in the CHOP group (24%)
Re-challenging efficacy evaluation
Re-challenging efficacy evaluation Re-challenge efficacy evaluationPeripheral neuropathy was relieved or improved in 72% (84/117) of the A+CHP group, 78% (97/124) in the CHOP group
.
.
In summary, the updated data of the ECHELON-2 study shows that A+CHP continues to improve the PFS and OS of patients with CD30+ peripheral T-cell lymphoma (PTCL) compared with CHOP, and at the same time significantly improves the peripheral neuropathy of the patients
.
.
The updated data of the ECHELON-2 study showed that A+CHP continued to improve the PFS and OS of CD30+ peripheral T-cell lymphoma (PTCL) patients compared with CHOP, and significantly improved the peripheral neuropathy of the patients
.
The updated data of the ECHELON-2 study showed that A+CHP continued to improve the PFS and OS of CD30+ peripheral T-cell lymphoma (PTCL) patients compared with CHOP, and significantly improved the peripheral neuropathy of the patients
.
Original source:
Original source:Horwitz S, O'Connor OA, Pro B, et al.
The ECHELON-2 Trial: 5-year results of a randomized, phase 3 study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.
Ann Oncol.
2021 Dec 15:S0923-7534(21)04875-4.
doi: 10.
1016/j.
annonc.
2021.
12.
002.
Epub ahead of print.
PMID: 34921960.
The ECHELON-2 Trial: 5-year results of a randomized, phase 3 study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.
Ann Oncol.
2021 Dec 15:S0923-7534(21)04875-4.
doi: 10.
1016/j.
annonc.
2021.
12.
002.
Epub ahead of print.
PMID: 34921960.
Leave a message here
